TIDMDPH

RNS Number : 6005L

Dechra Pharmaceuticals PLC

13 September 2021

13 September 2021

Dechra Pharmaceuticals PLC

(the Company or Dechra)

Notification of Transactions by Person Discharging Managerial Responsibilities

On 10 September 2021, Dechra Pharmaceuticals PLC was notified by a Director of the Company and Person Discharging Managerial Responsibilities that he had completed the sale of part of his beneficial interest in Dechra.

Tony Griffin, Executive Director, has sold 17,500 ordinary shares in the Company to satisfy long term personal financial planning considerations and widen his investment portfolio. Following this transaction, Tony Griffin will continue to retain a beneficial holding of 28,150 ordinary shares which represents 0.026% of the current issued share capital in the Company.

The Notification of Dealing Form set out below is provided in accordance with the UK Market Abuse Regulation.

Notification of Dealing Form:

 
 1.   Details of the Person Discharging Managerial Responsibility 
       ("PDMR")/person closely associated with them ("PCA") 
 a)   Name                                  Tony Griffin 
     ------------------------------------  ---------------------------------- 
 2.   Reason for the notification 
     ------------------------------------------------------------------------ 
 a)   Position/status                       Director 
     ------------------------------------  ---------------------------------- 
 b)   Initial notification/amendment        Initial Notification 
     ------------------------------------  ---------------------------------- 
 3.   Details of the Issuer 
     ------------------------------------------------------------------------ 
 a)   Name                                  Dechra Pharmaceuticals PLC 
     ------------------------------------  ---------------------------------- 
 b)   LEI code                              213800J4UVB5OWG8VX82 
     ------------------------------------  ---------------------------------- 
 4.   Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions have 
       been conducted 
     ------------------------------------------------------------------------ 
 a)   Description of the financial          Ordinary Shares of 1 pence each 
       instrument                            ISIN: GB0009633180 
       Identification code 
     ------------------------------------  ---------------------------------- 
 b)   Nature of the transaction             Sale of Shares 
     ------------------------------------  ---------------------------------- 
 c)   Price(s) and volumes(s)               Price(s)             Volume(s) 
                                             GBP50.01492          17,500 
     ------------------------------------  -------------------  ------------- 
 d)        Aggregated information 
             *    Aggregate volume            17,500 
                                              GBP50.01492 
                                              GBP875,261.10 
             *    Price 
 
 
             *    Total 
     ------------------------------------  ---------------------------------- 
 e)   Date of the transaction               10 September 2021 
     ------------------------------------  ---------------------------------- 
 f)   Place of the transaction              London Stock Exchange 
     ------------------------------------  ---------------------------------- 
 
 
 Enquiries: 
 Dechra Pharmaceuticals PLC 
 Ian Page, Chief Executive                 Office: +44 (0) 1606 814 730 
  Officer 
 Paul Sandland, Chief Financial            Office: +44 (0) 1606 814 730 
  Officer 
  e-mail: corporate.enquiries@dechra.com 
 
 TooleyStreet Communications 
  Ltd 
 Fiona Tooley, Director                    Office: +44 (0) 121 309 0099 
  e-mail: fiona@tooleystreet.com            Mobile: +44 (0) 7785 703 523 
----------------------------------------  ------------------------------ 
 

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBDGDCBUBDGBX

(END) Dow Jones Newswires

September 13, 2021 08:53 ET (12:53 GMT)

Grafico Azioni Dechra Pharmaceuticals (LSE:DPH)
Storico
Da Ott 2021 a Nov 2021 Clicca qui per i Grafici di Dechra Pharmaceuticals
Grafico Azioni Dechra Pharmaceuticals (LSE:DPH)
Storico
Da Nov 2020 a Nov 2021 Clicca qui per i Grafici di Dechra Pharmaceuticals